Sugi Predict

Sugi Predict / Compounds / SCHEMBL2384235

SCHEMBL2384235

SCHEMBL2384235

CC(C)(C)OC(=O)N1CCN(c2nsnc2Cl)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.48
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ GBA1 P04062 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ TLR9 Q9NR96 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ USP2 O75604 1/20 0.43
▸ LIPA P38571 3/20 0.43
▸ KIT P10721 1/20 0.42
▸ CKS1B P61024 1/20 0.42
▸ SKP1 P63208 1/20 0.42
▸ SKP2 Q13309 1/20 0.42
▸ STS P08842 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ GPR119 Q8TDV5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385404 0.95 MEN1 (0.50) POLBMEN1KMT2AGBA1MAPT
SCHEMBL18282608 0.84 SMARCA2 (0.49) GBA1MAPTALDH1A1LMNATLR9
SCHEMBL18282671 0.83 KIT (0.46) GBA1MAPTALDH1A1LMNATLR9
SCHEMBL18282513 0.83 GBA1 (0.43) GBA1MAPTALDH1A1LMNATLR9
SCHEMBL18282583 0.82 KIT (0.43) GBA1MAPTALDH1A1LMNATLR9
SCHEMBL18282571 0.81 NAMPT (0.43) MEN1KMT2AGBA1MAPTALDH1A1
SCHEMBL18282509 0.81 ALDH1A1 (0.43) MEN1KMT2AGBA1MAPTALDH1A1
SCHEMBL18282643 0.80 NR1H2 (0.46) GBA1MAPTALDH1A1LMNATLR9
SCHEMBL18282568 0.80 KIT (0.41) MEN1KMT2AGBA1MAPTALDH1A1
SCHEMBL20011912 0.79 POLB (0.47) POLBMEN1KMT2AGBA1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107709316-B 2- (1-heteroarylpiperazin-4-yl) methyl-1, 4-benzodioxane derivatives as alpha 2C antagonists 奥赖恩公司 2021-08-17 — — CN disclosed
US-10774074-B2 2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2C antagonists ORION CORPORATION (FI) 2020-09-15 — — US disclosed
US-10774074-B2 2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2C antagonists ORION CORPORATION (FI) 2020-09-15 — — US disclosed
EP-3303327-B1 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS ORION CORP (FI) 2020-03-11 — — EP disclosed
US-20190292170-A9 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS ORION CORPORATION (FI) 2019-09-26 — — US disclosed
US-20190292170-A9 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS ORION CORPORATION (FI) 2019-09-26 — — US disclosed
US-20180215739-A1 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS ORION CORPORATION (FI) 2018-08-02 — — US disclosed
US-20180215739-A1 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS ORION CORPORATION (FI) 2018-08-02 — — US disclosed
US-20180215739-A1 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS ORION CORPORATION (FI) 2018-08-02 — — US disclosed
EP-3303327-A1 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS Orion Corporation (FI) 2018-04-11 — — EP disclosed
EP-1487829-B1 THIADIAZOLYLPIPERAZINE DERIVATIVES USEFUL FOR TREATING OR PREVENTING PAIN EURO CELTIQUE SA (LU) 2007-10-10 — — EP disclosed
EP-1608373-A2 TIE-2 MODULATORS AND METHODS OF USE Exelixis Inc. (US) 2005-12-28 — — EP disclosed
WO-2004083235-A2 TIE-2 MODULATORS AND METHODS OF USE EXELIXIS INC. (US) 2004-09-30 — — WO disclosed
CN-1164580-C Oxadiazole derivatives as 5-hydroxytryptamine activators — 2004-09-01 — — CN disclosed
EP-1161424-B1 NEW DIAZOLE DERIVATIVES AS SEROTONERGIC AGENTS WYETH CORP (US) 2004-06-02 — — EP disclosed
WO-2003074520-A1 THIADIAZOLYLPIPERAZINE DERIVATIVES USEFUL FOR TREATING OR PREVENTING PAIN EURO-CELTIQUE, S.A. (LU) 2003-09-12 — — WO disclosed
CN-1349520-A Novel oxadiazole derivatives as 5-hydroxytryptamine drugs AMERICAN HOME PROD (US) 2002-05-15 — — CN disclosed
EP-1161424-A1 NEW DIAZOLE DERIVATIVES AS SEROTONERGIC AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 2001-12-12 — — EP disclosed
US-6239134-B1 TREATING CENTRAL NERVOUS SYSTEM DISORDERS USING THESE COMPOUNDS. NOVEL DIAZOLEPIPERAZINE, DIAZOLEPIPERIDINE, AND DIAZOLEDIHYDROPIPERIDINE DERIVATIVES, AMERICAN HOME PRODUCTS CORP. 2001-05-29 — — US disclosed
WO-2000051999-A1 NEW DIAZOLE DERIVATIVES AS SEROTONERGIC AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-09-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180215739-A1 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS OPRM1, HTR2C, ADRA2C POLB 3840/4885MEN1 2449/4885KMT2A 1293/4885
US-10774074-B2 2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2C antagonists OPRM1, HTR2C, ADRA2C POLB 3840/4885MEN1 2449/4885KMT2A 1293/4885
US-20190292170-A9 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS OPRM1, HTR2C, ADRA2C POLB 3840/4885MEN1 2449/4885KMT2A 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.